Loading the company…
Loading the company…
㈜씨케이
English name as filed with DART, Korea’s corporate disclosure system · Correct the English name ›
Last updated 2026-11-02 · Korean page ›
Verification level — how far we have checked
L0 · Public records — NPS workforce · filed financials · patents — public data
A company based in Seoul, founded in 1992. Industry: Bio & Pharma. Revenue for 2025 was ₩38.4bn. It has 63 employees enrolled in the National Pension Service (as of Aug 2026). It is externally audited; the latest audit opinion is “Unqualified”.
Loading…
Latest filing 2021-09-23 · latest registration 2024-11-27 · newest first
체중 및 체지방을 감소시키는 다이어트용 건강기능식품이 제공된다. 본 발명에 따른 다이어트용 건강기능식품은, 가르시니아캄보지아 추출물, 프락토올리고당 및 식이섬유 함유 선식을 포함한다. 상기 식이섬유 함유 선식과 상기 가르시니아캄보지아 추출물의 중량비는, 1:1 내지 1:3이다.
본 발명은 베이스 분말 30 내지 60 중량%, 새싹보리 핵분열 배아 발아 분말 30 내지 60 중량%, 및 첨가제 10 내지 30 중량%를 포함하여 변비 개선 및 소화 불량 개선 효과를 가지며 맛이 우수한 기능성 식품을 제공한다.
본 발명은 소프넛 껍질를 유효성분으로 하는 섬유 유연 기능성 세제 조성물에 대한 것이다. 본 발명에서 제공하는 소프넛 껍질은 우수한 세정력과 유연 효과를 동시에 나타내며, 중성에 가까운 pH를 나타내어 옷감 손상이나 피부 자극이 적어 친환경 섬유 유연 기능성 세제 조성물로 유용하게 사용될 수 있다.
KIPO KIPRIS · checked 2026-10-15 · newest filings first · right: registration date (filing date if not yet registered) · 3 of 3 · titles and abstracts are in Korean as filed · click a row for details ▾
For now we hold public records only (National Pension Service · DART filings · patents · registers · press). When the company files material in our IR Room, it moves to L1. We do not score or rate companies — we only state how far we have checked.
| KRW bn | 2024 | 2025 |
|---|---|---|
| Revenue | 35.8 | 38.4 |
| Cost of sales | 30.2 | 32.3 |
| Gross profit (loss) | 5.6 | 6.1 |
| Selling, general and administrative expenses | 4.4 | 5.7 |
| Operating income (loss) | 1.2 | 0.4 |
| Non-operating income | 0.3 | 0.7 |
| Other gains | 0.1 | 0.3 |
| Finance income | 0.0 | 0.0 |
| Other | 0.2 | 0.4 |
| Non-operating expenses | 1.3 | 1.1 |
| Other losses | 0.1 | 0.1 |
| Finance costs | 0.4 | 0.4 |
| Other | 0.8 | 0.6 |
| Profit (loss) before tax | 0.2 | (0.0) |
| Net income (loss) | 0.2 | (0.0) |
Revenue ₩38.4bn, up 7.2% YoY.
Operating margin 1.0% (prior 3.2%).
Net income ₩-0bn.
Need more than is shown here? Ask for more information — full review report · valuation · executive teaser · IM · competitor analysis · due diligence. Tell us what you need and we will reply by email with scope, cost and timing.
Is this your company?
If anything here is wrong, tell us — we check it against the original and correct it. You do not need to join. If you would like your financials verified and this page completed, that is a separate process.
Headlines and links to public articles only · not checked by us (original ↗) · articles are in Korean — English headlines are our translation; where none is shown, “Read in English ›” opens a machine translation · “Broker view” is a forecast, not reported results · checked 2026-11-06